{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:49:48Z","timestamp":1793321388643,"version":"4.5.0"},"reference-count":96,"publisher":"Georg Thieme Verlag KG","issue":"10","license":[{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hemophilia A, characterized by absent or ineffective coagulation factor VIII (FVIII), is a serious bleeding disorder that entails severe and potentially life-threatening bleeding events. Current standard therapy still involves replacement of FVIII, but is often complicated by the occurrence of neutralizing alloantibodies (inhibitors). Management of patients with inhibitors is challenging and necessitates immune tolerance induction for inhibitor eradication and the use of bypassing agents (activated prothrombin complex concentrates or recombinant activated factor VII), which are expensive and not always effective. Emicizumab is the first humanized bispecific monoclonal therapeutic antibody designed to replace the hemostatic function of activated FVIII by bridging activated factor IX and factor X (FX) to activate FX and allow the coagulation cascade to continue. In the majority of hemophilic patients with and without inhibitors, emicizumab reduced the annualized bleeding rate to almost zero in several clinical trials and demonstrated a good safety profile. However, the concurrent use of emicizumab and activated prothrombin complex concentrate imposes a high risk of thrombotic microangiopathy and thromboembolic events on patients and should be avoided. Yet, the management of breakthrough bleeds and surgery remains challenging with only limited evidence-based recommendations being available. This review summarizes published clinical trials and preliminary reports of emicizumab and discusses the clinical implications of emicizumab in treatment of hemophilia A.<\/jats:p>","DOI":"10.1055\/s-0040-1714279","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T19:20:35Z","timestamp":1595877635000},"page":"1357-1370","source":"Crossref","is-referenced-by-count":42,"title":["Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A"],"prefix":"10.1055","volume":"120","author":[{"given":"Georg","family":"Gelbenegger","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schoergenhofer","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Knoebl","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Jilma","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,7,27]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/(SICI)1096-8652(199812)59:4<288::AID-AJH4>3.0.CO;2-I","article-title":"Occurrence of hemophilia in the United States","volume":"59","author":"J M Soucie","year":"1998","journal-title":"Am J Hematol"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"A Srivastava","year":"2013","journal-title":"Haemophilia"},{"issue":"23","key":"ref3","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias--from royal genes to gene therapy","volume":"344","author":"P M Mannucci","year":"2001","journal-title":"N Engl J Med"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"V S Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1538-7836.2009.03717.x","article-title":"Mild hemophilia A","volume":"8","author":"M Franchini","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1055\/s-0032-1326786","article-title":"The diagnosis and management of congenital hemophilia","volume":"38","author":"M D Carcao","year":"2012","journal-title":"Semin Thromb Hemost"},{"issue":"05","key":"ref7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood-2018-08-872291","article-title":"New therapies for hemophilia","volume":"133","author":"A C Weyand","year":"2019","journal-title":"Blood"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.blre.2013.06.002","article-title":"Hemophilia A in the third millennium","volume":"27","author":"M Franchini","year":"2013","journal-title":"Blood Rev"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/hae.13327","article-title":"Monitoring joint health in haemophilia: Factors associated with deterioration","volume":"23","author":"I AR Kuijlaars","year":"2017","journal-title":"Haemophilia"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2141.2008.07386.x","article-title":"Understanding haemophilic arthropathy: an exploration of current open issues","volume":"143","author":"N W Jansen","year":"2008","journal-title":"Br J Haematol"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.hoc.2016.05.007","article-title":"The intrinsic pathway of coagulation as a target for antithrombotic therapy","volume":"30","author":"A P Wheeler","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/rth2.12162","article-title":"Polyphosphate in thrombosis, hemostasis, and inflammation","volume":"3","author":"C J Baker","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"ref13","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1182\/blood.V92.11.3983","article-title":"The life cycle of coagulation factor VIII in view of its structure and function","volume":"92","author":"P J Lenting","year":"1998","journal-title":"Blood"},{"issue":"14","key":"ref14","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/blood-2017-02-767079","article-title":"Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex","volume":"130","author":"Y Kamikubo","year":"2017","journal-title":"Blood"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/0192623310389474","article-title":"Continuing education course #2: current understanding of hemostasis","volume":"39","author":"A J Gale","year":"2011","journal-title":"Toxicol Pathol"},{"issue":"06","key":"ref16","first-page":"479","article-title":"Factor VIII replacement is still the standard of care in haemophilia A","volume":"17","author":"L Aledort","year":"2019","journal-title":"Blood Transfus"},{"issue":"03","key":"ref17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/13543784.2020.1723547","article-title":"Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A","volume":"29","author":"P M Mannucci","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"13","key":"ref18","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","article-title":"Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens","volume":"125","author":"J Oldenburg","year":"2015","journal-title":"Blood"},{"issue":"06","key":"ref19","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1046\/j.1365-2516.2002.00695.x","article-title":"Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome","volume":"8","author":"K Fischer","year":"2002","journal-title":"Haemophilia"},{"issue":"04","key":"ref20","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","article-title":"A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)","volume":"9","author":"A Gringeri","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref21","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"M J Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"17","key":"ref22","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood-2016-02-683169","article-title":"Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project","volume":"129","author":"M J Manco-Johnson","year":"2017","journal-title":"Blood"},{"issue":"04","key":"ref23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2796.1994.tb00815.x","article-title":"A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs","volume":"236","author":"L M Aledort","year":"1994","journal-title":"J Intern Med"},{"issue":"02","key":"ref24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/17474086.2018.1419862","article-title":"A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies","volume":"11","author":"E Santagostino","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2516.2010.02370.x","article-title":"Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia","volume":"17","author":"P W Collins","year":"2011","journal-title":"Haemophilia"},{"issue":"02","key":"ref26","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood.V81.2.412.412","article-title":"A multicenter study of viral hepatitis in a United States hemophilic population","volume":"81","author":"C L Troisi","year":"1993","journal-title":"Blood"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/jmv.1890410307","article-title":"Serologic markers of viral hepatitis A, B, C, and D in patients with hemophilia","volume":"41","author":"A Kumar","year":"1993","journal-title":"J Med Virol"},{"issue":"03","key":"ref28","first-page":"279","article-title":"HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study","volume":"7","author":"B L Kroner","year":"1994","journal-title":"J Acquir Immune Defic Syndr (1988)"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1046\/j.1537-2995.2001.41030338.x","article-title":"Risk factors for infection with HBV and HCV in a largecohort of hemophiliac males","volume":"41","author":"J M Soucie","year":"2001","journal-title":"Transfusion"},{"issue":"02","key":"ref30","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1182\/blood-2005-11-4407","article-title":"Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up","volume":"108","author":"D M Arnold","year":"2006","journal-title":"Blood"},{"issue":"05","key":"ref31","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.23957","article-title":"Impact of inhibitors on hemophilia A mortality in the United States","volume":"90","author":"C E Walsh","year":"2015","journal-title":"Am J Hematol"},{"issue":"S 04","key":"ref32","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1016\/j.amepre.2011.09.017","article-title":"Physical functioning in boys with hemophilia in the U.S","volume":"41","author":"P E Monahan","year":"2011","journal-title":"Am J Prev Med"},{"issue":"S 06","key":"ref33","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2516.2008.01885.x","article-title":"Articular status of haemophilia patients with inhibitors","volume":"14","author":"M Morfini","year":"2008","journal-title":"Haemophilia"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1365-2516.2009.02032.x","article-title":"Health-related quality of life and productivity impact in haemophilia patients with inhibitors","volume":"15","author":"T M Brown","year":"2009","journal-title":"Haemophilia"},{"issue":"02","key":"ref35","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2516.2011.02692.x","article-title":"Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008","volume":"18","author":"S Guh","year":"2012","journal-title":"Haemophilia"},{"issue":"S 06","key":"ref36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1365-2516.2006.01370.x","article-title":"Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors","volume":"12","author":"M Ullman","year":"2006","journal-title":"Haemophilia"},{"issue":"04","key":"ref37","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/ajh.1123","article-title":"Therapeutic choices for patients with hemophilia and high-titer inhibitors","volume":"67","author":"R Kulkarni","year":"2001","journal-title":"Am J Hematol"},{"issue":"01","key":"ref38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/2040620712464509","article-title":"Factor VIII inhibitors in hemophilia A: rationale and latest evidence","volume":"4","author":"C Witmer","year":"2013","journal-title":"Ther Adv Hematol"},{"issue":"02","key":"ref39","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ajh.20162","article-title":"Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction","volume":"77","author":"C A Leissinger","year":"2004","journal-title":"Am J Hematol"},{"issue":"S 04","key":"ref40","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1365-2516.2004.00993.x","article-title":"Inhibitors in haemophilia: clinical aspects","volume":"10","author":"D Dimichele","year":"2004","journal-title":"Haemophilia"},{"issue":"06","key":"ref41","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"C R Hay","year":"2012","journal-title":"Blood"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1055\/s-2003-37941","article-title":"Immune tolerance induction in hemophilia A: a review","volume":"29","author":"G Mariani","year":"2003","journal-title":"Semin Thromb Hemost"},{"issue":"09","key":"ref43","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/j.1538-7836.2009.03538.x","article-title":"The molecular mechanisms of immunomodulation and tolerance induction to factor VIII","volume":"7","author":"B Waters","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref44","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2003-03-0941","article-title":"Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group","volume":"102","author":"A Gringeri","year":"2003","journal-title":"Blood"},{"issue":"10","key":"ref45","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/2040620717721458","article-title":"Current and emerging factor VIII replacement products for hemophilia A","volume":"8","author":"L A Cafuir","year":"2017","journal-title":"Ther Adv Hematol"},{"issue":"10","key":"ref47","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"T Kitazawa","year":"2012","journal-title":"Nat Med"},{"issue":"07","key":"ref48","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"T Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"issue":"23","key":"ref49","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"P J Lenting","year":"2017","journal-title":"Blood"},{"issue":"15","key":"ref50","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s40265-019-01200-2","article-title":"Emicizumab: a review in haemophilia A","volume":"79","author":"H A Blair","year":"2019","journal-title":"Drugs"},{"issue":"13","key":"ref51","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects","volume":"127","author":"N Uchida","year":"2016","journal-title":"Blood"},{"issue":"21","key":"ref52","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"M Shima","year":"2016","journal-title":"N Engl J Med"},{"issue":"06","key":"ref53","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"S W Pipe","year":"2019","journal-title":"Lancet Haematol"},{"issue":"09","key":"ref55","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia a without inhibitors","volume":"379","author":"J Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"09","key":"ref56","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"J Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"ref57","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"G Young","year":"2019","journal-title":"Blood"},{"issue":"06","key":"ref60","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors","volume":"25","author":"M Shima","year":"2019","journal-title":"Haemophilia"},{"issue":"01","key":"ref62","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/hae.13877","article-title":"Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors","volume":"26","author":"P T Ebbert","year":"2020","journal-title":"Haemophilia"},{"issue":"11","key":"ref64","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1182\/bloodadvances.2019000228","article-title":"Emicizumab use in major orthopedic surgery","volume":"3","author":"C D Seaman","year":"2019","journal-title":"Blood Adv"},{"issue":"03","key":"ref66","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/rth2.12201","article-title":"Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention","volume":"3","author":"K E Dane","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"01","key":"ref67","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/hae.13618","article-title":"The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study","volume":"25","author":"J Oldenburg","year":"2019","journal-title":"Haemophilia"},{"issue":"09","key":"ref68","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1055\/s-0039-1692427","article-title":"Laboratory monitoring in emicizumab-treated persons with hemophilia A","volume":"119","author":"J M\u00fcller","year":"2019","journal-title":"Thromb Haemost"},{"issue":"07","key":"ref69","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-0039-1688687","article-title":"Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays","volume":"119","author":"J I Adamkewicz","year":"2019","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref72","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/hae.13903","article-title":"Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline","volume":"26","author":"P V Jenkins","year":"2020","journal-title":"Haemophilia"},{"issue":"S 01","key":"ref74","first-page":"3782","article-title":"A novel hemostatic monitoring system convertible to FVIII activity based on non-activated ROTEM (NATEM) for hemophilia A patients during emicizumab prophylaxis","volume":"132","author":"K Yada","year":"2018"},{"issue":"06","key":"ref76","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/jth.14022","article-title":"Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa\/factor X bispecific antibody emicizumab","volume":"16","author":"K Nogami","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref78","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.3324\/haematol.2017.185330","article-title":"Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab","volume":"103","author":"Y Dargaud","year":"2018","journal-title":"Haematologica"},{"issue":"09","key":"ref79","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/jth.14491","article-title":"Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program","volume":"17","author":"G G Levy","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref80","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/hae.13495","article-title":"Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee","volume":"24","author":"P W Collins","year":"2018","journal-title":"Haemophilia"},{"issue":"05","key":"ref81","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/hae.13817","article-title":"Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra\u00ae ): proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP)","volume":"25","author":"S Susen","year":"2019","journal-title":"Haemophilia"},{"issue":"02","key":"ref82","first-page":"143","article-title":"Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET","volume":"18","author":"G Castaman","year":"2020","journal-title":"Blood Transfus"},{"issue":"08","key":"ref83","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/jth.14556","article-title":"Emicizumab and thrombosis: The story so far","volume":"17","author":"M Makris","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref85","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1111\/j.1538-7836.2012.04871.x","article-title":"Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?","volume":"10","author":"C Hermans","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref86","first-page":"535","article-title":"Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management","volume":"16","author":"G Benson","year":"2018","journal-title":"Blood Transfus"},{"issue":"11","key":"ref87","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood-2013-02-483263","article-title":"Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A","volume":"122","author":"C L Eckhardt","year":"2013","journal-title":"Blood"},{"issue":"07","key":"ref88","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1055\/s-0038-1660852","article-title":"Hemostasis in the very young","volume":"44","author":"G Kenet","year":"2018","journal-title":"Semin Thromb Hemost"},{"issue":"11","key":"ref89","doi-asserted-by":"crossref","first-page":"e27886","DOI":"10.1002\/pbc.27886","article-title":"Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort","volume":"66","author":"A A Barg","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"02","key":"ref90","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40272-020-00382-7","article-title":"Pharmacokinetics and clinical pharmacology of monoclonal antibodies in pediatric patients","volume":"22","author":"Z H Temrikar","year":"2020","journal-title":"Paediatr Drugs"},{"issue":"20","key":"ref91","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/bloodadvances.2018015842","article-title":"Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance","volume":"2","author":"G Young","year":"2018","journal-title":"Blood Adv"},{"issue":"19","key":"ref92","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMc1909742","article-title":"Deaths associated with emicizumab in patients with hemophilia A","volume":"381","author":"L M Aledort","year":"2019","journal-title":"N Engl J Med"},{"issue":"02","key":"ref93","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/ejh.13193","article-title":"Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients","volume":"102","author":"R Ljung","year":"2019","journal-title":"Eur J Haematol"},{"issue":"S 01","key":"ref94","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/hae.12051","article-title":"The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?","volume":"19","author":"C E Ettingshausen","year":"2013","journal-title":"Haemophilia"},{"issue":"05","key":"ref95","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/hae.13819","article-title":"Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis","volume":"25","author":"G Batsuli","year":"2019","journal-title":"Haemophilia"},{"issue":"04","key":"ref96","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/hae.13762","article-title":"The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab","volume":"25","author":"M Carcao","year":"2019","journal-title":"Haemophilia"},{"issue":"09","key":"ref97","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s40262-017-0616-3","article-title":"A pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A","volume":"57","author":"K Yoneyama","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.12659\/AJCR.916783","article-title":"Emicizumab use in treatment of acquired hemophilia A: a case report","volume":"20","author":"K Al-Banaa","year":"2019","journal-title":"Am J Case Rep"},{"issue":"02","key":"ref99","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000497287","article-title":"Emicizumab in the treatment of acquired haemophilia: a case report","volume":"46","author":"P M\u00f6hnle","year":"2019","journal-title":"Transfus Med Hemother"},{"issue":"18","key":"ref100","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s40265-018-1027-y","article-title":"Prevention and management of bleeding episodes in patients with acquired hemophilia A","volume":"78","author":"P Kn\u00f6bl","year":"2018","journal-title":"Drugs"},{"issue":"S 01","key":"ref101","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1182\/blood-2018-99-116973","article-title":"Emicizumab for the treatment of acquired hemophilia_A: lessons learned from 4 very different cases","volume":"132","author":"P Knoebl","year":"2018","journal-title":"Blood"},{"issue":"18","key":"ref103","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1182\/bloodadvances.2019000656","article-title":"Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies","volume":"3","author":"A C Weyand","year":"2019","journal-title":"Blood Adv"},{"issue":"S 01","key":"ref105","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1182\/blood-2018-99-112418","article-title":"Model of short and long-term outcomes of emicizumab prophylaxis treatment for persons with hemophilia A","volume":"132","author":"A Mahajerin","year":"2018","journal-title":"Blood"},{"issue":"02","key":"ref106","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1055\/s-0039-3401822","article-title":"Cost-effectiveness and budget impact of emicizumab prophylaxis in haemophilia A patients with inhibitors","volume":"120","author":"P A Cortesi","year":"2020","journal-title":"Thromb Haemost"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"100618","DOI":"10.1016\/j.blre.2019.100618","article-title":"Paradigm shift for the treatment of hereditary haemophilia: towards precision medicine","volume":"39","author":"G Spadarella","year":"2020","journal-title":"Blood Rev"},{"issue":"S 02","key":"ref108","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0049-3848(16)30359-0","article-title":"Targeting TFPI for hemophilia treatment","volume":"141","author":"J A Peterson","year":"2016","journal-title":"Thromb Res"},{"issue":"05","key":"ref109","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"P Chowdary","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref110","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of antithrombin in hemophilia A or B with RNAi therapy","volume":"377","author":"K J Pasi","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"ref111","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"S Rangarajan","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1714279.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T18:55:06Z","timestamp":1696445706000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1714279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,27]]},"references-count":96,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,9,23]]},"published-print":{"date-parts":[[2020,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1714279","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,27]]}}}